tx.
Roth Capital has a 4 handle on it and I tend to agree. VRX paid 1 billion for Addi (Sprout Pharma's version) and that came with a black box warning for starters.
PTN already has stated via an 8K:
"...an agreement, Palatin engaged Catalent to manufacture drug product and prefilled syringes, assemble prefilled syringes into an auto-injector device, and package and label the combination product (such final combination product, the "Product"). Palatin intends to engage third parties to provide Catalent with a supply of bremelanotide and the disposable auto-injector device.
Catalent will have the right to supply at least 80% of Palatin's needs for the Product during the term of the Agreement. Palatin entered into the Agreement in anticipation of approval by the U.S. Food and Drug Administration (the "FDA") of the Product..."
They obviously have lots of confidence that phase III should go well. They've also publicly stated (and verified via Roth analyst) that discussions and partnering arrangements are already happening. (This was back in May).
Anyway, you and I both know that companies will, can, and do say anything to get press and positive buzz. In addition, the FDA does what it wants to do regardless. However, I think the steady buying this month going into August bodes well. I'm counting on a partnership/arrangement announcement prior to September's top-line results. I like the odds on this one.
Theo 
;-)
;-) 
